Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Discontinuation of Statins in Routine Care Settings
Groen, Piet C. de

Annals of Internal Medicine | July 1, 2013 | Volume: 159 | Issue: 1 | Pages: 74

10.7326/0003-4819-159-1-201307020-00020 | PMID 23817714 Get It

Brief Report: Accelerated Aging Influences Cardiovascular Disease Risk in Rheumatoid Arthritis
Crowson, Cynthia S. , Therneau, Terry M. , Davis, John M. , Roger, Véronique L. , Matteson, Eric L. , Gabriel, Sherine E., Davis, John M

Arthritis & Rheumatism | July 1, 2013 | Volume: 65 | Issue: 10 | Pages: 2562-2566

10.1002/art.38071 | PMID 23818136 Get It

ObjectiveTo determine whether the impact of aging on cardiovascular disease (CVD) risk in patients with rheumatoid arthritis (RA) differs from that in the general population (as estimated by the Framingham Risk Score [FRS]).MethodsA population‐based inception cohort of Olmsted County, Minnesota residents ages ≥30 years who fulfilled the American College of Rheumatology 1987 criteria for RA in 1988–2008 was assembled and followed up until death, migration, or July 1, 2012. Data on CVD events were collected by medical records review. The 10‐year FRS for CVD was calculated. Cox models adjusted for FRS were used to examine the influence of age on CVD risk.ResultsThe study included 563 patients with RA without prior CVD (mean age 55 years, 72% women, and 69% seropositive [i.e., rheumatoid factor and/or anti–citrullinated protein antibody positive]). During a mean followup of 8.2 years, 98 patients developed CVD (74 seropositive and 24 seronegative), but the FRS predicted only 59.7 events (35.4 seropositive and 24.3 seronegative). The gap between observed and predicted CVD risk increased exponentially across age, and the effect of age on CVD risk in seropositive RA was nearly double its effect in the general population, with additional log(age) coefficients of 2.91 for women (P = 0.002) and 2.06 for men (P = 0.027).ConclusionOur findings indicate that age exerts an exponentially increasing effect on CVD risk in seropositive RA, but no increased effect among seronegative patients. The causes of accelerated aging in patients with seropositive RA deserve further investigation.
Evolution of longitudinally extensive transverse myelitis in an aquaporin-4 IgG-positive patient
Asgari, Nasrin , Skejoe, Hanne Pernille Bro, Lennon, Vanda A.

Neurology | July 1, 2013 | Volume: 81 | Issue: 1 | Pages: 95-96

10.1212/wnl.0b013e318297ef07 | PMID 23817516 Get It

Teaching Neuro Images : Diagnostic utility of FDG-PET in neurolymphomatosis
Toledano, Michel , Siddiqui, Mustaqeem , Thompson, Carrie A. , Garza, Ivan , Pittock, Sean J. , Pittock, S J , Siddiqui, Mustaqeem A , Toledano, Michel

Neurology | July 1, 2013 | Volume: 81 | Issue: 1 | Pages: No page available

10.1212/wnl.0b013e318297eef5 | PMID 23817522 Get It

Darkness at the End of the Tunnel: Poststenotic Kidney Injury
Eirin, Alfonso , Lerman, Lilach O. , Eirin, Alfonso

Physiology | July 1, 2013 | Volume: 28 | Issue: 4 | Pages: 245-253

10.1152/physiol.00010.2013 | PMID 23817799 Get It

Renal artery stenosis remains an important contributor to renal failure in the elderly population, but uncertainty continues to surround the mechanisms underlying progressive renal dysfunction. Here, we present the current understanding of the pathogenic mechanisms responsible for renal injury in these patients, with emphasis on those involved in disease progression.
Early Recognition and Treatment of Severe Sepsis
Ramar, Kannan , Gajic, Ognjen

American Journal of Respiratory and Critical Care Medicine | July 1, 2013 | Volume: 188 | Issue: 1 | Pages: 7-8

10.1164/rccm.201304-0801ed | PMID 23815716 Get It

In reference to what are the diagnostic criteria for migraine‐associated vertigo?
Brookler, Kenneth H.

The Laryngoscope | July 1, 2013 | Volume: 124 | Issue: 4 | Pages: No page available

10.1002/lary.24288 | PMID 23818170 Get It

Idiopathic subglottic stenosis: An evolving therapeutic algorithm
Maldonado, Fabien , Loiselle, Andrea, DePew, Zachary S. , Edell, Eric S. , Ekbom, Dale C. , Malinchoc, Michael, Hagen, Clinton E., Alon, Eran E. , Kasperbauer, Jan L.

The Laryngoscope | July 1, 2013 | Volume: 124 | Issue: 2 | Pages: 498-503

10.1002/lary.24287 | PMID 23818139 Get It

Discordant CD34+ cell results in peripheral blood and hematopoietic progenitor cell–apheresis product: implications for clinical decisions and impact on patient treatment
Liwski, Courtney J, Padley, Douglas, Gastineau, Dennis A. , Jacob, Eapen K., Gustafson, Michael P. , Winters, Jeffrey L.

Transfusion | July 1, 2013 | Volume: 54 | Issue: 3 | Pages: 541-544

10.1111/trf.12324 | PMID 23808629 Get It

Case ReportA 50‐year‐old male with T‐cell lymphoma presented for autologous peripheral blood stem cell transplantation. After granulocyte–colony‐stimulating factor (G‐CSF) mobilization, his peripheral blood CD34+ cell count was 166 × 106/L on the day before collection, which predicted a high yield of CD34+ cells in the apheresis product. The first two collections had yields much lower than expected, triggering an investigation and changes to the apheresis collection methods since mobilization appeared adequate from the peripheral CD34+ values.ResultsChanges to the apheresis collection variables and instrumentation did not improve the yields in the next three collections. The laboratory investigation demonstrated that there was an interfering substance in the patient's plasma that was causing falsely high peripheral blood CD34+ cell values and that the low CD34+ cell yields in the collections were consistent with the actual peripheral blood CD34+ cell value. Based on this finding and after discussion with the clinical service, the patient then received plerixafor to increase the number of circulating CD34+ cells before Collections 6 and 7. The patient went on to achieve the target CD34+ cell dose and subsequently underwent a successful autologous transplant with full hematopoietic engraftment.ConclusionThis case demonstrates the importance of timely and critical review of laboratory results in the context of the specific patient. This case exemplifies how diligent review of laboratory results and open communication among the various teams can positively affect patient outcomes.
Differences in Healthcare Utilization and Associated Costs Between Patients Prescribed vs. Nonprescribed Opioids During an Inpatient or Emergency Department Visit
Xie, Lin , Joshi, Ashish V. , Schaaf, David, Mardekian, Jack , Shah, Nilay D., Başer, Onur , Harnett, James

Pain Practice | July 1, 2013 | Volume: 14 | Issue: 5 | Pages: 446-456

10.1111/papr.12098 | PMID 23809064 Get It

AbstractObjectivesCompare healthcare resource utilization (HCRU) and costs between patients prescribed opioids (RxOP) and those who were not (NoRxOP) during an emergency department (ED) or inpatient visit.MethodsRetrospective cohort analysis was performed (January 2006 to September 2010). Continuously eligible RxOP patients in ED/inpatient settings (January 2007 to September 2009) were included if age was ≥ 12 years by initial prescription date (or random date between first ED/inpatient admission and September 30, 2009 [NoRxOP patients]).Healthcare resource utilization and costs for 12 months after initial prescription were compared. Univariate descriptive analyses were performed for baseline and outcome variables and compared using appropriate tests. Risk adjustment compared HCRU between RxOP and NoRxOP cohorts for the postindex period.ResultsOf 27,599 eligible patients, RxOP patients (n = 18,819) were younger, less likely to be male, more likely to reside in southern United States and to have Preferred Provider Organization health plans, and had lower comorbidity index scores, compared with NoRxOP patients (n = 8,780). RxOP patients were less likely to have nonpain‐related comorbidities and more frequently diagnosed with pain‐related comorbidities.Unmatched and propensity‐matched RxOP patients experienced higher HCRU and costs in all subcategories (total, inpatient, outpatient ED, physician, pharmacy, other outpatient settings). Opioid abuse frequency was low in patients with common diagnoses/procedures within 3 months before initial prescription (0.48%). Average time to abuse was < 1 year (201 days).ConclusionMost patients were prescribed opioids initially during ED/inpatient visits and incurred higher HCRU than those not prescribed opioids. Among those with diagnosed opioid abuse after initiating opioids, time to diagnosis was rapid (range: 14 to 260 days) for patients with common diseases and procedures.